Pluristem Therapeutics (NASDAQ:PSTI) Downgraded by Zacks Investment Research to Hold

0
25

Pluristem Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Pluristem Therapeutics Downgraded by Zacks Investment Research on 6/30/2020. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Pluristem Therapeutics traded up $0.04 on Tuesday, reaching $8.54. 141073 shares of the stock traded hands, compared to its average volume of 705992. Shares of Pluristem Therapeutics at mid-way on Tuesday were at $8.54. The firm’s 50 day moving average is $8.65 and its 200 day moving average is $5.10.Pluristem Therapeutics  has a 12 month low of $8.35 and a 12 month high of $13.29. While on yearly highs and lows, Pluristem Therapeutics’s today has traded high as $8.74 and has touched $8.35 on the downward trend. See More Analyst Rating at: RATING

Pluristem Therapeutics Earnings and What to expect: 

Earnings for Pluristem Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.12) per share. The P/E ratio of Pluristem Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Pluristem Therapeutics is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Pluristem Therapeutics has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 4.90%
  • On 6/18/2020 Major Shareholder Clover Wolf Capital – Limited Buy 49,000 at average share price of $7.36 which equates to $360,640.00 in money value.
  • On 6/10/2020 Major Shareholder Clover Wolf Capital – Limited Buy 25,000 at average price of  $6.91 with total value of : Not Data Available
  • On 6/8/2020 Major Shareholder Clover Wolf Capital – Limited Buy 178,717 at average price of  $7.36 with total value of : $1,315,357.12

Analyst at Zacks Investment Research are also talking about :

  • 6/19/2020 – Pluristem Therapeutics is now covered by analysts at Jefferies Financial Group Inc. They set a “buy” rating and a $12.00 price target on the stock.
  • 5/15/2020 – Pluristem Therapeutics had its “buy” rating re-affirmed by analysts at Maxim Group. They now have a $12.00 price target on the stock.
  • 5/14/2020 – Pluristem Therapeutics had its “buy” rating re-affirmed by analysts at HC Wainwright. They now have a $15.50 price target on the stock.
  • 4/23/2020 – Pluristem Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating.

Pluristem Therapeutics (NASDAQ:PSTI) Moving Average Technical Analysis

5 day Moving Average is $8.62 And 5 day price change is $0.35 (4.35%)  with average volume for 5 day average is 575,124. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $7.83 and 20 day price change is $0.72 (9.37%) and average 20 day moving volume is 571,126. 50 day moving average is $8.65  and 50 day price change is -$0.29 ( -3.34%)  and with average volume for 50 days is : 1,445,974. 200 day moving average is $5.10  and 200 day price change is $4.00 (90.91%)  and with average volume for 200 days is : 860,687.

See More Analyst Rating at: RATING